Inhibikase Shares Interim 3-Month Toxicology Studies Data Of Parkinson's Candidate - Inhibikase Therapeutics (NASDAQ:IKT)

Inhibikase Therapeutics Inc IKT has announced interim three-month results from its ongoing chronic toxicology studies of oral IkT-148009 administered in rats and non-human primates (NHPs).
The toxicology studies of IkT-148009 include daily oral administration in rats for six months and in NHPs for nine months.
Additionally, Inhibikase added three-month dosing cohorts in rats and NHPs to support an evaluation in Parkinson's patients for up to three months in its planned Phase 2a study.
Previously submitted 14-day toxicology data in rats and NHPs showed No Adverse Event Level (NOAEL), a measure of drug safety in animals, determined to be 31.2 mg in NHPs, but could not be determined in rats.
Following three months of dosing, NOAEL measurements in rats and NHPs were 50 mg and 75 mg, respectively, representing a 2.4-fold increase in NHPs and establishing a standard for rats.
Following FDA review of these three-month toxicology results, the Company plans to initiate a Phase 2a study in 2022 to evaluate daily oral administration of IkT-148009 in up to 120 Parkinson's patients out to three months.
Related Link: Inhibikase To Start Testing Its Parkinson's Candidate In Patients.
Price Action: IKT shares are up 2.02% at $1.97 during the market session on the last check Monday.